A major global pharma company approached Certara scientists to develop a virtual Chinese population to assist with decision-making regarding clinical trials.
Certara leverages its modeling and simulation technology to facilitate regulatory approval for a targeted treatment for melanoma.
Leveraging the US FDA’s accelerated approval programs, Pharmacyclic generated PBPK models using the Simcyp Simulator to inform dose, dosing regimens, and DDIs.
Modeling and simulation approaches help immuno-oncology programs establish dosing regimens, inform the drug label, and make better decisions on competitive positioning.
A global top-10 pharma company engaged in an initiative using Certara’s D360 to better address cross-study analysis of pre-clinical safety data.
A small biotech company used Certara’s D360 to better address access and analysis of chemical and biological data by its scientists.
A global pharma company leveraged Certara’s Phoenix modeling platform to enhance the capabilities of their clinical pharmacology and pharmacometrics groups.
A top-40 pharma company enhanced data access and decision support for pre-clinical safety with Certara’s D360 and a specialized CDISC SEND-based database.